Conversely, when the anti-cancer effects of a combination therapy with paclitaxel and S13 (a tyrosine kinase inhibitor with a prevalent specificity for Src) were analyzed in a hormone-insensible prostate cancer cell model, tumor growth and angiogenesis were suppressed by the concomitant impairment of endothelial migration and VEGF production [113]. The gene discussed is VEGFA; the disease is Familial prostate cancer.